Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Revenue (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Revenue readings, the most recent being $18.6 million for Q4 2025.

  • On a quarterly basis, Revenue rose 9.76% to $18.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.0 million, a 0.58% increase, with the full-year FY2025 number at $65.3 million, down 3.42% from a year prior.
  • Revenue hit $18.6 million in Q4 2025 for Enanta Pharmaceuticals, up from $15.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $27.6 million in Q4 2021 to a low of $14.6 million in Q3 2024.
  • Median Revenue over the past 5 years was $18.7 million (2022), compared with a mean of $19.1 million.
  • The widest YoY moves for Revenue: up 15.93% in 2021, down 27.11% in 2021.
  • Enanta Pharmaceuticals' Revenue stood at $27.6 million in 2021, then fell by 14.7% to $23.6 million in 2022, then dropped by 23.67% to $18.0 million in 2023, then fell by 5.8% to $17.0 million in 2024, then rose by 9.76% to $18.6 million in 2025.
  • The last three reported values for Revenue were $18.6 million (Q4 2025), $15.1 million (Q3 2025), and $18.3 million (Q2 2025) per Business Quant data.